< 1 minute read
Sep. 18, 2021

BMS-986143: An Oral Reversible Selective BTK Kinase Inhibitor

BMS-986143

oral reversible selective BTK kinase inhibitor related cmpds in dev. for inflamm. conditions from rational design of prior crystallized leads ACS Med. Chem. Lett., Sep. 22, 2020 Bristol Myers Squibb, Princeton, NJ

twitterlinkedinprintemail